Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503) for $65 million on January 23, 2023. Under the terms, Sandoz AG will pay $62.5 to 75 million upfront, depending on the date of the closing of the transaction, and potential sales-based milestone payments. The transaction is subject to regulatory approvals and standard conditions and is expected to complete in the first half of 2023.

As of August 18, 2023, The transaction is expected to close in the second half of 2023. Christoph W.G. Engeler of Latham & Watkins acted as legal advisor for Astellas Pharma.